NeuroPace narrows Q1 loss to $0.13 per share, beats estimates and ups revenue outlook
NPCE•NeuroPace narrowed its Q1 loss to $0.13 per share compared with a $0.21 loss a year ago, beating the consensus estimate by $0.06. The company also lifted its full-year 2026 revenue outlook following stronger-than-expected quarterly results.
1. Q1 Earnings Beat Estimates
NeuroPace reported a Q1 net loss of $0.13 per share, outperforming the consensus loss estimate of $0.19 per share. The EPS outperformance reflected improved operational efficiencies and higher-than-anticipated sales of its RNS® System.
2. Year-Over-Year Improvement
The quarterly loss narrowed by 38% from $0.21 per share in Q1 2025, driven by a reduction in operating expenses and steady revenue growth. This marks the second consecutive quarter of year-over-year EPS improvement.
3. Raised 2026 Revenue Guidance
In light of robust first-quarter performance, NeuroPace increased its 2026 revenue guidance, signaling confidence in sustained device adoption. Management cited expanding reimbursement coverage and an accelerating sales pipeline as key factors supporting the outlook.
